WuXi Biologics Reports 16.7% Revenue Growth and Strong Margin Expansion in 2025

WuXi Biologics (2269.HK) announced its annual financial results for 2025, showcasing robust growth across its key financial metrics. The company reported a 16.7% increase in total revenue, driven by the successful execution of its CRDMO business model and operational excellence. A significant highlight was the expansion of the gross profit margin, which rose by 5 percentage points to reach 46.0%, reflecting high cost-management efficiency. IFRS gross profit saw a substantial year-on-year increase of 30.9%, supported by the company's advanced digital-native infrastructure. Management attributed these gains to comprehensive digital transformation and sophisticated technical capabilities that bolstered its competitive edge. These strong results underscore the company's ability to maintain sustainable profitability within the global biotech sector despite broader economic challenges.

Sources:prnewswire.comchemxplore.commarketscreener.comtipranks.comfinance.biggo.comdaytraders.comglobenewswire.com